Phathom Pharmaceuticals, Inc.: financial analysis
Ratios worked out from 8 fiscal years of Phathom Pharmaceuticals, Inc.'s statements, compared with 665 companies in Biotechnology.
Phathom Pharmaceuticals, Inc. scorecard#
Passes 3 of the 15 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median1.8×Price to sales 1.8× against Biotechnology's median of 8.8×.
- ✗Free cash flow yield above 5%-33.0%Free cash flow is -33.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- ✓Revenue grew in the newest year216.9%Revenue up 216.9% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.03 vs -5.29Diluted EPS -3.03 in fiscal 2025 against -5.29 the year before (report's currency).
- ✗Net income higher than five years earlier-$221 M-$221 M in fiscal 2025 against -$129 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$221 MNet income -$221 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-91.4%-91.4% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.73 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-8.50Z-score -8.50 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year15.4%Diluted shares up 15.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $221 million, the 8th loss-making year in a row.
- Free cash flow was negative: -$167 million.
- The share count rose 15.4% in the year.
- Shareholders' equity is negative: -$438 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsno
- Current ratio roseno
- No new shares issuedno
- Gross margin roseyes
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.37 | × 1.2 | 0.45 |
| Retained earnings to assets | -5.73 | × 1.4 | -8.02 |
| Operating income to assets | -0.62 | × 3.3 | -2.04 |
| Market value to liabilities | 0.72 | × 0.6 | 0.44 |
| Revenue to assets | 0.68 | × 1 | 0.68 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 87.1% | 85.6% | — | — | — | 74.8% | 66% | |
| Operating margin | -91.4% | -502.2% | — | — | — | -60.5% | 46% | |
| Net margin | -126.4% | -605.1% | — | — | — | -68.9% | 40% | |
| Return on equity | — | — | — | — | -108.0% | -61.0% | — | |
| Return on assets | -69.4% | -84.4% | -69.7% | -111.6% | -59.4% | -44.4% | 31% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 216.9% | — | — | — | — | 15.8% | 93% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | — | — | — | 1.24× | 0.26× | — | |
| Net debt | $79 M | $-96 M | $-244 M | $-60 M | $-94 M | $-16 M | 14% | |
| Interest cover | — | — | -3.99× | -6.32× | -19.89× | -22.77× | — | |
| Current ratio | 1.73× | 4.20× | 10.25× | 6.12× | 9.86× | 4.39× | 20% | |
| Equity share of assets | -169.1% | -67.0% | -17.6% | -45.4% | 38.1% | 64.7% | 5% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-167 M | $-267 M | $-139 M | $-148 M | $-149 M | $-40 M | 15% | |
| Free cash flow margin | -95.4% | -483.1% | — | — | — | -61.5% | 44% | |
| Capital spending share of revenue | 0.1% | 0.3% | — | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.55× | 0.14× | — | — | — | 0.26× | 74% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).